It covers methods that build or modify glycoprotein sugar structures using isolated enzymes, enzyme cascades or cell-free lysates rather than living host cells, plus the supporting chemistry — sugar nucleotide supply, cofactor recycling — and the analytics used to check the result, such as site occupancy and product homogeneity testing. This dataset defines the field by that combination of process and verification terms, which is why analytical classes like G01N and G16B show up alongside the core chemistry classes. A search built only on the reaction chemistry would miss a meaningful share of records that are really about proving the product is consistent.

The ranking covers 48 companies, with one clear leader at 59 records, a fifth-place assignee at 10, and a tenth-place assignee down to 3 — a steep drop within the first ten positions. That shape points to one or two platform-scale incumbents surrounded by a long tail of universities and smaller biotechs with a handful of families each. Anyone benchmarking competitive position should look at the gap between the leader and fifth place specifically, since it is far larger than the gap between fifth and tenth.

Filings peaked at 16 in 2020 and have since settled lower, but the last fully comparable window — 2021 to 2024 — shows a 50% increase, from 2 filings up to 3. Because publication typically lags actual filing by around 18 months, the 2025 and 2026 figures in any raw chart will look artificially low and should not be read as a real slowdown. The honest read is modest but real growth off a post-2020 base, not decline.